Since the inhibition of miR-34a in a mice model improved hepatic steatosis by increasing PPARα levels promoting lipid oxidation [74], targeting miR-34a/PPARα signaling holds promise as an interesting future strategy for clinical miRNA therapeutic applications against NAFLD. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.